A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1

Blood

Volumn 116, Issue 6, 2010, Pages 893-899

  Lukina, Elena ^a   Watman, Nora ^b   Arreguin, Elsa Avila ^c   Banikazemi, Maryam ^d,k   Dragosky, Marta ^e   Iastrebner, Marcelo ^e   Rosenbaum, Hanna ^f   Phillips, Mici ^g   Pastores, Gregory M ^d   Rosenthal, Daniel I ^h   Kaper, Mathilde ⁱ   Singh, Tejdip ⁱ   Puga, Ana Cristina ⁱ   Bonate, Peter L ^i,j   Peterschmitt, M Judith ⁱ  

^a NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^b HOSPITAL RAMOS MEJÍA   (Argentina)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d NEW YORK UNIVERSITY   (United States)

^e Instituto Argentino de Diagnostico y Tratamiento   (Argentina)

^f RAMBAM MEDICAL CENTER   (Israel)

^g SHAARE ZEDEK MEDICAL CENTER   (Israel)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ GENZYME CORPORATION   (United States)

^j GLAXOSMITHKLINE   (United States)

^k Och Spine at New York Presbyterian Hospitals   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954538917     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-273151     Document Type: Article

References (22)

1. Beutler E, Grabowski G. Gaucher disease. In: Scriver CR, Beaudet A, Sly W, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:3635-3668.
2. Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995;122(1):33-39.
3. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(4 suppl 5):4-14. (Pubitemid 39311677)
4. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002;113(2):112-119.
5. Vunnam RR, Radin NS. Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem Phys Lipids. 1980;26(3):265-278.
6. Miglustat [package insert]. Allschwil, Switzerland: Actelion Pharmaceuticals Ltd; 2008.
7. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000;355(9214):1481-1485. (Pubitemid 30237353)
8. Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J Biol Chem. 1999;274(21):14662-14669.
9. McEachern KA, Fung J, Komarnitsky S, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab. 2007;91(3):259-267. (Pubitemid 46819125)
10. Peterschmitt MJ, Burke A, Blankstein L, et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol. In press.
11. Rosenthal DI, Doppelt SH, Mankin HJ, et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics. 1995;96(4):629-637.
12. Rosenthal DI, Scott JA, Barranger J, et al. Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg Am. 1986;68(6):802-808. (Pubitemid 16074356)
13. Baim S, Binkley N, Bilezikian JP, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom. 2008;11(1):75-91. (Pubitemid 351339091)
14. Rogers WH, Wittink H, Wagner A, Cynn D, Carr DB. Assessing individual outcomes during outpatient multidisciplinary chronic pain treatment by means of an augmented SF-36. Pain Med. 2000;1(1):44-54.
15. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-1123. (Pubitemid 19246303)
16. Pomponio RJ, Cabrera-Salazar MA, Echeverri OY, Miller G, Barrera LA. Gaucher disease in Colombia: mutation identification and comparison to other Hispanic populations. Mol Genet Metab. 2005;86(4):466-472. (Pubitemid 41796489)
17. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease. J Clin Invest. 1994;93(3):1288-1292. (Pubitemid 24087186)
18. Grabowski GA, Kacena K, Cole JA, et al. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med. 2009;11(2):92-100.
19. Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res. 2007;22(1):119-126. (Pubitemid 46032604)
20. Pastores GM, Elstein D, Hrebicek M, Zimran A. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther. 2007;29(8):1645-1654. (Pubitemid 47494543)
21. Boot RG, van Breemen MJ, Wegdam W, et al. Gaucher disease: a model disorder for biomarker discovery. Expert Rev Proteomics. 2009;6(4):411-419.
22. Langeveld M, Ghauharali KJ, Sauerwein HP, et al. Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J Clin Endocrinol Metab. 2008;93(3):845-851. (Pubitemid 351398562)